公开(公告)号：US20240327518A1

公开(公告)日：2024-10-03

申请号：US18294516

申请日：2022-08-05

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Wenxin XU ,  Xuefei FANG ,  Deyu XU ,  Lieming DING

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68

CPC classification number: C07K16/2818 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569

Abstract: Provided are an anti-PD-L1 nanobody and use thereof. The anti-PD-L1 nanobody comprises a CDR1, a CDR2, and a CDR3, wherein the CDR1 comprises a sequence selected from SEQ ID NOs: 1, 5, and 9; the CDR2 comprises a sequence selected from SEQ ID NOs: 2, 6, and 10; and the CDR3 comprises a sequence selected from SEQ ID NOs: 3, 7, 11, and 14. The antibody can block the PD-1/PD-L1 and CD-80/PD-L1 signaling pathways, inhibit the growth of tumor cells, and exhibit a therapeutic effect against tumors.

公开(公告)号：US20240383974A1

公开(公告)日：2024-11-21

申请号：US18692312

申请日：2022-09-29

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Wenxin XU ,  Xuefei FANG ,  Deyu XU ,  Jieying XU ,  Lieming DING

IPC: C07K16/22 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

Abstract: Provided are a bispecific antibody and use thereof. The bispecific antibody provided can specifically bind to TGF-β, GARP, or GARP-TGF-β complex individually or simultaneously, and can also specifically bind to PD-L1. The bispecific antibody provided exhibits high affinity and specificity for the antigens, has a tumor-killing effect, and can be applied to the treatment of tumors.